metal-organic papers

Acta Crystallographica Section E Structure Reports Online

ISSN 1600-5368

Mervi Kontturi,^a* Sirpa Peräniemi,^b Jouko J. Vepsäläinen^b and Markku Ahlgrén^a

^aUniversity of Joensuu, Department of Chemistry, PO Box 111, FI-80101 Joensuu, Finland, and ^bUniversity of Kuopio, Department of Chemistry, PO Box 1627, FI-70211 Kuopio, Finland

Correspondence e-mail: mervi.kontturi@joensuu.fi

Key indicators

Single-crystal X-ray study T = 120 KMean σ (P–C) = 0.004 Å R factor = 0.019 wR factor = 0.047 Data-to-parameter ratio = 17.1

For details of how these key indicators were automatically derived from the article, see http://journals.iucr.org/e.

Pentaaqua(dichloromethylenebisphosphonato)strontium(II)

The title compound, $[Sr{Cl_2C(PO_3H)_2}(H_2O)_5]$, is a monomer, the Sr atom being seven-coordinated by one chelating clodronate ligand and five aqua ligands. The coordination polyhedron can be described as a distorted monocapped trigonal prism. This compound is isostructural with hydrated calcium clodronate, $[Ca{Cl_2C(PO_3H)_2}(H_2O)_5]$, described previously [Nardelli, Pelizzi, Staibano & Zucchi (1983). *Inorg. Chim. Acta*, **80**, 259–271]. Received 21 June 2004 Accepted 28 June 2004 Online 9 July 2004

Comment

Bisphosphonates are an interesting class of compounds because of their pharmaceutical applications (Fleisch, 1995; Fleisch et al., 1969; Kanis & McCloskey, 1990; Bijvoet et al., 1995) and their potential chemical applications in, for example, ion exchange, sorption and catalysis (Zhang & Clearfield, 1997; Alberti et al., 1996; Snover et al., 1996; Serre & Férey, 2002). Clodronate, the anion of disodium (dichloromethylene)bisphosphonate tetrahydrate, is one of the best documented methylenebisphosphonate derivatives and is used effectively in medical applications (Major et al., 2000). Clodronate has six possible O-donor atoms, and we can therefore presume that it also forms polymeric structures that can be utilized in chemical applications. The previously reported crystal structure of hydrated calcium clodronate, [Ca{Cl₂C(PO₃H)₂](H₂O)₅], revealed that clodronate itself acted only as a bidentate chelating ligand with Ca, forming a monomeric compound (Nardelli et al., 1983). Our latest results, on the other hand, show that both clodronate and its partial ester derivative can also produce polymers (Kontturi et al., 2002, 2004). The new strontium complex of clodronate, $[Sr{Cl_2C(PO_3H)_2}(H_2O)_5]$, (I), is a monomer, and its preparation and crystal structure are reported here.



The title compound consists of one Sr^{2+} atom, one chelating $\mathrm{Cl}_2\mathrm{C}(\mathrm{PO}_3\mathrm{H})_2{}^{2-}$ ligand and five aqua ligands (Fig. 1). The compound is isostructural with the corresponding calcium clodronate, $[\mathrm{Ca}\{\mathrm{Cl}_2\mathrm{C}(\mathrm{PO}_3\mathrm{H})_2\}(\mathrm{H}_2\mathrm{O})_5]$ (Nardelli *et al.*, 1983).

© 2004 International Union of Crystallography Printed in Great Britain – all rights reserved

 D_m measured by flotation in cyclo-

hexane/bromoform

Cell parameters from 2674

Mo $K\alpha$ radiation

reflections $\theta = 2.6 - 26.0^{\circ}$

 $\mu = 4.63 \text{ mm}^{-1}$

T = 120 (2) K

 $\begin{aligned} R_{\rm int} &= 0.057\\ \theta_{\rm max} &= 26.0^\circ \end{aligned}$

 $h=-12\rightarrow 12$

 $k = -14 \rightarrow 14$

 $l = -13 \rightarrow 13$

Cube, colourless

 $0.35 \times 0.35 \times 0.35 \mbox{ mm}$

2674 independent reflections

2596 reflections with $I > 2\sigma(I)$



Figure 1

Molecular structure of (I), with the atom-numbering scheme and 50% probability displacement ellipsoids.



Figure 2 Packing diagram of (I), showing large pores in the direction of the *a* axis, formed between the hydrogen-bonded (dashed lines) units.

However, the methods of preparation of the compounds are different; the strontium compound was prepared with the gel method, while the calcium compound was prepared by slow evaporation at 333 K. On the other hand, we have also produced calcium clodronate using the gel method (Kontturi et al., 2004). In the Sr compound, the Sr atom is sevencoordinate, and the coordination polyhedron can be described as a distorted monocapped trigonal prism. One O atom from each of the phosphonate groups of the $Cl_2C(PO_3H)_2^{2-}$ ligand (O11 and O21) coordinates to the Sr atom to form a chelate ring, the 'bite' distance for O11...O21 being 3.136 (2) Å. The second O atom of the two phosphonate groups is doubly bonded to P, and the third is protonated. The monomeric units are packed through intermolecular hydrogen bonds. Twelve hydrogen bonds are present, the two strongest being formed by the protonated phosphonate atoms O13 and O23, which are donors to atoms O12 and O22 of the Cl₂C(PO₃H)₂²⁻ ligands of adjacent molecules. The other hydrogen bonds involve all aqua ligands as donors and O atoms of $Cl_2C(PO_3H)_2^{2-}$ and aqua ligands as acceptors. The packing diagram (Fig. 2) shows large pores between the hydrogenbonded units, in the direction of the *a* axis.

Experimental

Compound (I) was crystallized by the gel method (Kontturi *et al.*, 2002, 2004) with disodium (dichloromethylene)bisphosphonate tetrahydrate (0.014 mmol, 5.0 mg) and SrCl₂·6H₂O (0.017 mmol, 4.6 mg) in water (0.9 ml, pH 4), using tetramethoxysilane (0.1 ml). Acetone (1.0 ml) was used as precipitant. Crystals formed in the shape of cubes above the gel, and were purified for characterization under the microscope. Analysis found: C 2.70, H 3.20, Sr 20.7%; calculated for CH₁₂Cl₂O₁₁P₂Sr: C 2.86, H 2.88, Sr 20.8%. IR (cm⁻¹): 1252 (*s*, *b*), 1193 (*vs*, *b*), 1124 (*vs*), 1085 (*m*), 1070 (*w*), 932 (*vs*), 863 (*vw*), 758 (*m*). ³¹P CP/MAS–NMR: 7.13 p.p.m.

Crystal data

 $[Sr(CH_2Cl_2O_6P_2)(H_2O)_5]$ $M_r = 420.57$ Orthorhombic, $Pna2_1$ a = 10.5207 (1) Å b = 11.8587 (1) Å c = 10.9164 (2) Å V = 1361.95 (3) Å³ Z = 4 $D_x = 2.051 \text{ Mg m}^{-3}$ $D_m = 2.02$ (4) Mg m⁻³

Data collection

Nonius KappaCCD diffractometer φ and ω scans Absorption correction: multi-scan (XPREP in SHELXTL; Bruker, 1998) $T_{\min} = 0.182, T_{\max} = 0.198$ 17 202 measured reflections

Refinement

Refinement on F^2 $(\Delta/\sigma)_{\rm max} < 0.001$ -3 $R[F^2 > 2\sigma(F^2)] = 0.019$ $\Delta \rho_{\rm max} = 0.33 \ {\rm e} \ {\rm \AA}^2$ $wR(F^2) = 0.047$ $\Delta \rho_{\rm min} = -0.56 \ {\rm e} \ {\rm \AA}^{-3}$ Extinction correction: SHELXL97 S = 1.082674 reflections Extinction coefficient: 0.0028 (4) 156 parameters Absolute structure: Flack (1983), H-atom parameters constrained 1260 Friedel pairs $w = 1/[\sigma^2(F_o^2) + (0.02P)^2]$ Flack parameter = 0.504(5)+ 0.6P] where $P = (F_o^2 + 2F_c^2)/3$

Table 1

Selected geometric parameters (Å, °).

2.499 (2)	P1-O11	1.495 (3)
2.500 (2)	P1-O12	1.503 (3)
2.524 (2)	P1-O13	1.568 (2)
2.542 (1)	P1-C1	1.849 (4)
2.552 (2)	P2-O21	1.484 (2)
2.576 (2)	P2-O22	1.499 (3)
2.609 (2)	P2-O23	1.566 (2)
1.800 (2)	P2-C1	1.856 (4)
1.784 (2)		
106.8 (1)	Cl2-C1-Cl1	109.3 (1)
107.6(1)	Cl2-C1-P1	108.6 (2)
104.3 (1)	Cl1-C1-P1	107.4 (2)
107.0 (1)	Cl2-C1-P2	108.6 (2)
106.8 (1)	Cl1-C1-P2	106.9 (2)
103.7 (1)	P1-C1-P2	115.9 (1)
	$\begin{array}{c} 2.499\ (2)\\ 2.500\ (2)\\ 2.524\ (2)\\ 2.542\ (1)\\ 2.576\ (2)\\ 2.676\ (2)\\ 2.609\ (2)\\ 1.800\ (2)\\ 1.784\ (2)\\ 106.8\ (1)\\ 107.6\ (1)\\ 107.6\ (1)\\ 107.8\ (1)\\ 107.8\ (1)\\ 107.8\ (1)\\ 103.7\ (1)\\ \end{array}$	$\begin{array}{ccccc} 2.499 & (2) & P1-O11 \\ 2.500 & (2) & P1-O12 \\ 2.524 & (2) & P1-O13 \\ 2.542 & (1) & P1-C1 \\ 2.552 & (2) & P2-O21 \\ 2.576 & (2) & P2-O22 \\ 2.609 & (2) & P2-O23 \\ 1.800 & (2) & P2-C1 \\ 1.784 & (2) \\ \end{array}$ $\begin{array}{cccccccccccccccccccccccccccccccccccc$

Table 2		
Hydrogen-bonding geometry	(Å,	°).

$D - H \cdots A$	D-H	$H \cdot \cdot \cdot A$	$D \cdots A$	$D - \mathbf{H} \cdot \cdot \cdot A$
01-H1A···O13 ⁱ	0.85	2.03	2.865 (3)	168
$O1 - H1B \cdot \cdot \cdot O22^{ii}$	0.85	2.03	2.773 (3)	145
$O2-H2A\cdots O12^{ii}$	0.85	1.97	2.755 (3)	153
$O2-H2B\cdots O23^{iii}$	0.85	2.02	2.841 (3)	162
$O3-H3A\cdots O21^{iii}$	0.85	2.01	2.793 (3)	152
$O3-H3B\cdots O1^{iii}$	0.85	2.10	2.890 (3)	155
$O4-H4B\cdots Cl1^{iv}$	0.85	2.72	3.554 (3)	167
$O4-H4A\cdots O11^{i}$	0.85	1.93	2.768 (3)	167
$O5-H5A\cdots O2^{v}$	0.85	2.11	2.955 (3)	171
$O5-H5B\cdots O12^{ii}$	0.85	2.29	2.987 (3)	139
$O13-H13\cdots O22^{vi}$	0.94	1.68	2.558 (4)	154
O23−H23···O12 ^{vii}	0.85	1.73	2.546 (3)	161

Symmetry codes: (i) $-x, 1-y, z-\frac{1}{2}$; (ii) $x-\frac{1}{2}, \frac{3}{2}-y, z$; (iii) $-x, 1-y, \frac{1}{2}+z$; (iv) $x-\frac{1}{2}, \frac{1}{2}-y, z$; (v) $\frac{1}{2}+x, \frac{3}{2}-y, z$; (vi) $1-x, 1-y, \frac{1}{2}+z$; (vii) $1-x, 1-y, z-\frac{1}{2}$.

There is a pseudo-centre of symmetry in the structure, and the structure was solved as an inversion twin in space group $Pna2_1$, as opposed to centrosymmetric Pnma. The solution in space group Pnma was not satisfactory; the displacements of the coordinated aqua ligands were, on average, larger in Pnma than in $Pna2_1$. In particular, the displacement ellipsoid of aqua ligand O3 was large and prolate. Also, the s.u. values of the bond distances and angles in Pnma were three times the s.u. values in $Pna2_1$; the R factor for observed reflections was three times greater and wR was four times greater in Pnma than in $Pna2_1$. H atoms of the aqua ligands were found in a difference map and then placed at optimized positions, taking into account potential hydrogen bonds [O-H = 0.85 Å]; a riding model was used, with $U_{iso}(H) = 1.5U_{eq}(O)$. Atoms H13 and H23 were found in difference maps, and a riding model was used, with $U_{iso}(H) = 1.5U_{eq}(O)$.

Data collection: COLLECT (Nonius, 1997); cell refinement: DENZO and SCALEPACK (Otwinowski & Minor, 1997); data

reduction: *DENZO* and *SCALEPACK*; program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *XP* in *SHELXTL* (Bruker, 1998); software used to prepare material for publication: *SHELXL97*.

References

- Alberti, G., Casciola, M., Constantino, U. & Vivani, R. (1996). Adv. Mater. 8, 291–303.
- Bijvoet, O. L. M., Fleisch, H. A., Canfield, R. E. & Russell, R. G. G. (1995). Bisphosphonates in Bones. Amsterdam: Elsevier.
- Bruker (1998). SHELXTL. Version 5.1. Bruker AXS Inc., Madison, Winsconsin, USA.
- Flack, H. D. (1983). Acta Cryst. A39, 876-881.
- Fleisch, H. (1995). *Bisphosphonates in Bone Disease: From the Laboratory to the Patient*. New York: The Parthenon Publishing Group Inc.
- Fleisch, H., Russel, R. G. G., Simpson, B. & Muchlbauer, R. C. (1969). Nature (London), 223, 211–212.
- Kanis, J. A. & McCloskey, E. V. (1990). Progress in Basic Clinical Pharmacology, 4th ed., pp. 89–136. Basel: Karger.
- Kontturi, M., Peräniemi, S., Vepsäläinen, J. J. & Ahlgrén, M. (2004). Eur. J. Inorg. Chem. In the press.
- Kontturi, M., Vuokila-Laine, E., Peräniemi, S., Pakkanen, T. T., Vepsäläinen, J. J. & Ahlgrén, M. (2002). J. Chem. Soc. Dalton Trans. pp. 1969–1973.
- Major, P. P., Lipton, A., Berenson, J. & Hortobagyi, G. H. (2000). Cancer, 88, 6–14.
- Nardelli, M., Pelizzi, G., Staibano, G. & Zucchi, E. (1983). *Inorg. Chim. Acta*, **80**, 259–271.
- Nonius (1997). COLLECT. Nonius BV, Delft, The Netherlands.
- Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
- Serre, C. & Férey, G. (2002). J. Mater. Chem. 12, 2367-2369.
- Sheldrick, G. M. (1997). SHELXS97 and SHELXL97. University of Göttingen, Germany.
- Snover, J. L., Byrd, H., Suponeva, E. P., Vicenzi, E. & Thompson, M. E. (1996). *Chem. Mater.* 8, 1490–1499.
- Zhang, B. & Clearfield, A. (1997). J. Am. Chem. Soc. 119, 2751-2752.